Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / UNIT 10/15/2029
-
Number of holders
-
9
-
Total 13F shares, excl. options
-
986K
-
Shares change
-
-2.3M
-
Total reported value, excl. options
-
$10.2M
-
Value change
-
-$23.4M
-
Number of buys
-
3
-
Number of sells
-
-10
-
Price
-
$10.32
Significant Holders of Drugs Made In America Acquisition Corp. - UNIT 10/15/2029 (DMAAU) as of Q2 2025
17 filings reported holding DMAAU - Drugs Made In America Acquisition Corp. - UNIT 10/15/2029 as of Q2 2025.
Drugs Made In America Acquisition Corp. - UNIT 10/15/2029 (DMAAU) has 9 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 986K shares
.
Largest 10 shareholders include RIVERNORTH CAPITAL MANAGEMENT, LLC (420K shares), Context Capital Management, LLC (250K shares), WOLVERINE ASSET MANAGEMENT LLC (130K shares), Bulldog Investors, LLP (57.3K shares), CLEAR STREET LLC (45.9K shares), ROBINSON CAPITAL MANAGEMENT, LLC (30K shares), Tuttle Capital Management, LLC (20K shares), UBS Group AG (18.4K shares), CITADEL ADVISORS LLC (14K shares), and Parallax Volatility Advisers, L.P. (0 shares).
This table shows the top 9 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.